DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Bis(4-aminophenyl) ether

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
LTEA_HepaRG_CYP1A1	Liver	Human	1543	CYP1A1	Inhibitory	37.53 μM
LTEA_HepaRG_CYP1A2	Liver	Human	1544	CYP1A2	Activatory	40.73 μM
LTEA_HepaRG_CYP2B6	Liver	Human	1555	CYP2B6	Inhibitory	67.0 μM
LTEA_HepaRG_FABP1	Liver	Human	2168	FABP1	Activatory	50.0 μM
LTEA_HepaRG_UGT1A1	Liver	Human	54658	UGT1A1	Activatory	78.86 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_AIME_384WELL_LUC_Active	Mammary gland/breast	Human	2099	ESR1	Gain	117.65 μM
CCTE_Deisenroth_AIME_384WELL_LUC_Inactive	Mammary gland/breast	Human	2099	ESR1	Gain	111.09 μM
HCAN_AUR_hTPO	Kidney	Human	7173	TPO	Loss	0.78 μM
CCTE_GLTED_hTBG		Human	6906	SERPINA7	Loss	25.34 μM
CCTE_GLTED_hTTR_0.125uM		Human	7276	TTR	Loss	12.08 μM
NVS_ADME_hCYP2B6		Human	1555	CYP2B6	Loss	2.55 μM
NVS_ADME_hCYP2C19		Human	1557	CYP2C19	Loss	4.39 μM
NVS_ADME_hCYP3A4		Human	1576	CYP3A4	Loss	5.64 μM
NVS_ENZ_hMMP2		Human	4313	MMP2	Loss	19.24 μM
NVS_ENZ_hPTPN6		Human	5777	PTPN6	Loss	17.02 μM
NVS_ENZ_rMAOAC	Brain	Rat	29253	Maoa	Loss	11.33 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	2.03 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	3.08 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	45.07 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	44.38 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	12.75 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.72 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	65.6 μM
TOX21_AhR_LUC_Agonist	Liver	Human	196	AHR	Gain	16.6 μM
TOX21_CAR_LUC_Agonist	Liver	Human	9970	NR1I3	Gain	58.93 μM
TOX21_AChE_Fluor_Antagonist	Bone	Human	43	ACHE	Loss	11.56 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	58.32 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	31.68 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	39.23 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	18.04 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	9.97 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	46.32 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	46.08 μM
TOX21_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	67.39 μM
TOX21_AChE_Fluor_Antagonist	Bone	Human	43	ACHE	Loss	16.69 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	46.08 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	48.09 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	34.02 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	19.03 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	11.26 μM

ToxCast endpoints for intended target type: Molecular messenger

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CEETOX_H295R_11DCORT	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	25.04 μM
CEETOX_H295R_OHPREG	Adrenal gland	Human	5241	PGR	Inhibitory	5.04 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Inhibitory	1.56 μM
CEETOX_H295R_CORTIC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	0.49 μM
CEETOX_H295R_CORTISOL	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Activatory	27.13 μM
CEETOX_H295R_DOC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	1.21 μM
CEETOX_H295R_ESTRADIOL	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Inhibitory	34.44 μM
CEETOX_H295R_ESTRONE	Adrenal gland	Human	2099\|2100	ESR1\|ESR2	Inhibitory	35.88 μM
CEETOX_H295R_PROG	Adrenal gland	Human	5241	PGR	Inhibitory	9.14 μM
CEETOX_H295R_TESTO	Adrenal gland	Human	367	AR	Inhibitory	1.02 μM

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
ACEA_AR_antagonist_80hr	Prostate	Human	367	AR	Loss	27.64 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratio	Ovary	Chinese hamster	3014	H2AX	Gain	113.62 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.